Hummingbird Bioscience

Hummingbird Bioscience is a biotechnology company developing precision biotherapeutics, with a focus on creating new treatment options for patients who may not respond to current therapies. Building on its experience in biologics discovery and development, the company uses proprietary technology platforms, including linker-payload technologies, to engineer antibody-based medicines. Its pipeline includes next-generation therapeutics such as antibody-drug conjugates (ADCs), as well as oncology and autoimmune programs, with potential to address other disease targets.

The company’s approach combines precision biology, precision therapy development, and clinical research. It prioritizes targets in cancer supported by strong biological rationale and clinical validation, then applies its platforms to discover and engineer therapies intended to deliver deep, durable responses. Hummingbird Bioscience also designs and conducts global clinical trials, aiming to assess treatments and make new medicines available to patients as quickly as possible. Its named pipeline programs include HMBD-001 and HMBD-501. Based in Singapore, the company also shares scientific publications and insights and welcomes partnering inquiries.